Ortiv-Q3 Research

What Ortiv-Q3 Research does

Ortiv-Q3 Research is an India-based pre-launch pharmaceutical services company headquartered in Ahmedabad, India, offering drug release testing services for dosage forms ranging from simple tablets to transdermal formulations. The company's stated functional focus is in-vitro characterization of drug release profiles, positioning it as a specialized analytical testing provider serving pharmaceutical manufacturers and formulators. As of 2025, the firm remains in a pre-commercial phase: its website (ortiv.in) displays a 'Launching Soon' message, no pricing or product portfolio is publicly disclosed, and no customers, partnerships, certifications, funding rounds, or revenue figures have been reported in the available data.

Operationally, the company is led by Mukesh Kumar (Founder & Director) with a small team of 1-10 employees, and is privately held with no disclosed parent company, subsidiaries, investors, or institutional shareholders. The legal entity is referenced as 'Ortiv' and the firm is based in Ahmedabad — a hub of India's pharmaceutical manufacturing industry — which provides locational proximity to potential customers but no disclosed commercial activity yet. There is no published technology stack, no AI/ML capability claims, no patent portfolio, no regulatory approvals, and no marketing or distribution channels disclosed, leaving the business model mechanics — how it will price services, contract with clients, or scale capacity — entirely unspecified at present.

The available data indicates the venture is at the earliest organizational stage: a registered entity with a founder, a placeholder web presence, and a defined service niche, but without confirmed commercial operations, revenue, or third-party validation. Diligence would need to clarify the discrepancy between firmographic founding year (2019) and the founded_year record (2025), confirm actual operational and revenue status, and surface any undisclosed lab capacity, accreditation (e.g., GLP, ISO 17025), or anchor customer relationships.

Name

Ortiv-Q3 Research

Legal name

Ortiv

Website

https://ortiv.in

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Ortiv-Q3 Research is an India-based pre-launch pharmaceutical services company in Ahmedabad offering drug release testing for dosage forms from simple tablets to transdermal formulations, intended to serve pharmaceutical manufacturers and formulators. The firm is led by founder Mukesh Kumar and is not yet commercially operating.

Ownership category

akta.pro rank

Product category

Pharmaceutical Testing Services

NAICS

Testing Laboratories and Services (541380), Testing Laboratories and Services (54138)

SIC

Services-Testing Laboratories (8734)

akta.pro primary industry

Release Testing & Batch Certification (QC) (HLAGADAC)

akta.pro secondary industry

Analytical Testing & QC Release Services (potency, purity, sterility) (HLAAAKAG)

Keywords

• Drug release testing
• Pharmaceutical testing
• Dosage form analysis
• Dissolution testing
• Transdermal testing

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Core offering

Ortiv-Q3 Research provides drug release testing services for pharmaceutical dosage forms ranging from simple tablets to transdermal formulations. The company is in pre-launch phase and operates from Ahmedabad, India, preparing to offer analytical laboratory testing services to pharmaceutical clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Release Testing Service Analytical laboratory drug release testing service for pharmaceutical dosage forms, covering a range from simple tablets to transdermal formulations. Intended for pharmaceutical companies and formulation developers requiring release characterization testing.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Lambda Therapeutic Research: Indian CRO providing bioanalytical, clinical and pharmaceutical laboratory services including formulation and release testing support. Comparable as an India-based contract testing services provider to pharma clients.
• Vimta Labs: Indian testing laboratory offering pharmaceutical and biopharmaceutical analytical and release testing services alongside food/environmental testing. Closest functional peer given its pharma- and formulation-focused release and stability testing franchise.
• Arbro Pharmaceuticals (Analytical Division): India-based pharmaceutical testing and contract laboratory with a focus on formulation analytical and release testing. The closest small-to-mid Indian functional comp to Ortiv-Q3 Research's stated offering.

Broad incumbents

• Intertek India: Global TIC firm with Indian pharma testing operations supporting formulation manufacturers with QC, release and stability work. Overlaps with Ortiv-Q3 Research's release testing focus but at vastly larger scale and scope.
• Eurofins India (Eurofins Biopharma Product Testing): Indian arm of the global Eurofins network providing pharmaceutical and biopharmaceutical product testing including dissolution and release testing. Highly comparable service line, but operates with global scale, broad portfolio, and established accreditations.
• Syngene International: Major India-based CRO/CDMO offering analytical services including dissolution and release testing among a broad discovery-through-manufacturing portfolio. Comparable as it serves pharma formulation clients needing QC release work, though much larger and diversified than Ortiv-Q3 Research.
• SGS India (Life Sciences): India operations of global testing/inspection company SGS offering pharmaceutical release and stability testing among a broad testing menu. Comparable through its pharmaceutical QC offering, though anchored in a diversified TIC portfolio.
• Charles River Laboratories: Global biopharma testing services provider offering release and QC analytical services via its Manufacturing Solutions segment. Compares via the same release-testing service, though anchored in biologics/biopharma at global scale.
• Sai Life Sciences: India-headquartered CRO/CDMO with an analytical services arm providing method development and release testing for drug product clients. Comparable in the analytical QC service line though it operates at significantly greater scale.
• Piramal Pharma Solutions: India-based CDMO with integrated analytical and release testing offerings within its drug-product services franchise. Comparable through the release-testing capability though embedded in a much wider CDMO offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ortiv-Q3 Research